Clinical trial

Phase

Study arm

Trial population

Primary outcome

BIBF 1120 in bevacizumab resistant, persistent, or recurrent EOC

2

BIBF 1120 200 mg bid daily

Recurrent or persistent EOC, progression or less than 6 months bevacizumab including treatment-free interval

PFS

Veliparib monotherapy for relapsed EOC with BRCA mutation (Veli-BRCA)

1, 2

Veliparib 300 mg bid daily

Histologically confirmed EOC, with germline BRCA1/2 mutations

Platinum resistance or partially platinum sensitive disease

Response rate

Feasibility and clinical activity of initial IP catumaxomab followed by chemotherapy in patients with recurrent EOC

2

Catumaxomab 10, 20, 50, 150 µg IP infusion on day 0, 3, 7, 10

Recurrent ovarian cancer

Feasibility

Intraperitoneal therapy for ovarian cancer with carboplatin trial (iPocc)

2, 3

IV paclitaxel: 80 mg/m², on day 1, 8, 15

IP carboplatin: AUC = 6 on day 1

Stage II-IV EOC, scheduled to undergo laparotomy

(both optimal and suboptimal patients will be eligible)

PFS

First-line intraperitoneal cisplatin and etoposide chemotherapy for ovarian cancer (AICE)

2

IP: cisplatin 50 mg/m², etoposide 100 mg/m², weekly, 4 cycles

Followed IV: paclitaxel 175 mg/m² plus carboplatin AUC 5 or docetaxel 60 - 75 mg/m² plus carboplatin AUC 5 after 14 days

Stage IIIc or IV, expect for lymph node metastasis alone, EOC

Optimal cytoreductive surgery, with a residual disease ≤1 cm

12-month disease non- progression rate

GANNET53: ganetespib in metastatic, p53-mutant, Platinum-resistant EOC

1, 2

IV paclitaxel, 80 mg/m²

Ganetespib on day 1, 8, 15 per 28-days cycle

High-grade serous, high-grade endometrioid, or undifferentiated EOC. Primary platinum-resistant disease

PFS

A study of rucaparib in patients with platinum-sensitive, relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (ARIEL2)

2

Rucaparib twice a day

High-grade (serous or endometrioid histology) EOC

Relapsed/progressive disease as confirmed by CT scan

Received ≥1 prior platinum-based treatment regimen

PFS

Bevacizumab and trabectedin +/− carboplatin in advanced EOC

2

Bevacizumab (15 mg/kg) followed by trabectedin (1.1 mg/m²) every 21 days

EOC with PFS between 6 - 12 months

PFS at 6-months

A study of pertuzumab in combination with standard chemotherapy in women with recurrent platinum-resistant EOC and Low HER3 mRNA expression

3

IV pertuzumab 840 mg followed by 420 mg every 3 weeks with standard chemotherapy

Platinum-resistant or refractory EOC, with low HER3 mRNA expression

Safety, PFS

Bevacizumab beyond progression in platinum sensitive ovarian cancer

3

Chemotherapy (pegylated liposomal doxorubicin, gemcitabine, paclitaxel) and bevacizumab

EOC with recurrence or progression at least 6 months after the last chemotherapy including bevacizumab

PFS

Phase II study of KPT-330 (selinexor) in female patients with advanced gynaecologic malignancies (SIGN)

2

Oral KPT-330 at 50 mg/m² twice weekly

EOC: platinum refractory and platinum resistant patients

Response rate

Temsirolimus, carboplatin, and paclitaxel as first-line therapy in treating patients with newly diagnosed stage III-IV clear cell ovarian cancer

2

Paclitaxel and carboplatin chemotherapy plus temsirolimus IV on days 1 and 8.

Consolidation: temsirolimus IV on days 1, 8, 15

Clear cell ovarian cancer at least 50% clear cell histomorphology

Activity,

PFS

A randomized study of DNIB0600A in comparison with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer

2

DNIB0600A 2.4 mg/kg IV every three weeks

Progressed or relapsed EOC during or within 6 months after the most recent treatment with a platinum-containing chemotherapy regimen and for whom PLD is appropriate therapy

PFS